GAMMA Investing LLC Purchases 28,615 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

GAMMA Investing LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 11,972.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,854 shares of the biotechnology company’s stock after acquiring an additional 28,615 shares during the period. GAMMA Investing LLC’s holdings in Blueprint Medicines were worth $2,554,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. California State Teachers Retirement System boosted its holdings in Blueprint Medicines by 4.9% in the fourth quarter. California State Teachers Retirement System now owns 59,259 shares of the biotechnology company’s stock worth $5,169,000 after acquiring an additional 2,742 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Blueprint Medicines by 99.6% in the fourth quarter. Mackenzie Financial Corp now owns 14,177 shares of the biotechnology company’s stock worth $1,237,000 after acquiring an additional 7,076 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Blueprint Medicines in the fourth quarter worth approximately $116,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Blueprint Medicines by 5.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,946 shares of the biotechnology company’s stock worth $20,928,000 after acquiring an additional 12,035 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Blueprint Medicines by 19.1% in the fourth quarter. Woodline Partners LP now owns 540,192 shares of the biotechnology company’s stock worth $47,116,000 after acquiring an additional 86,614 shares in the last quarter.

Insider Activity

In other news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total value of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares of the company’s stock, valued at approximately $14,830,158.20. The trade was a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ariel Hurley sold 2,752 shares of the business’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the sale, the insider now directly owns 16,944 shares of the company’s stock, valued at approximately $1,747,434.72. This trade represents a 13.97% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,574 shares of company stock valued at $1,465,528. Insiders own 4.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BPMC. JMP Securities restated a “market perform” rating on shares of Blueprint Medicines in a report on Tuesday, June 3rd. Wall Street Zen upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 2nd. HC Wainwright reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, May 2nd. Citigroup raised Blueprint Medicines from a “strong sell” rating to a “hold” rating and lifted their price objective for the company from $83.00 to $129.00 in a research note on Wednesday, June 4th. Finally, UBS Group lifted their price objective on Blueprint Medicines from $88.00 to $129.00 and gave the company a “neutral” rating in a research note on Thursday, June 5th. Seventeen research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $129.35.

Blueprint Medicines Trading Up 0.2%

Shares of BPMC stock opened at $128.21 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The business has a 50-day moving average price of $99.05 and a two-hundred day moving average price of $96.79. Blueprint Medicines Co. has a 12-month low of $73.04 and a 12-month high of $128.34. The firm has a market cap of $8.28 billion, a P/E ratio of -118.71 and a beta of 0.84.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million during the quarter, compared to the consensus estimate of $158.31 million. During the same period last year, the firm posted $1.40 EPS. The company’s revenue was up 55.5% on a year-over-year basis. Equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.